First Patient Enrolled in Europe in Phase II Clinical trial
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Regulatory approval for Phase II trial in France and Austria
- ATH434 Clinical Trial Launched in Italy
- ATH434 clinical trial launched in the US
- New US patent for compounds to treat neurodegeneration
- ATH434 Clinical Trial launched in Australia
Later from Alterity Therapeutics
- US patent grant and license agreement
- Appendix 4C and Quarterly Cash Flow Report
- ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
- Investor Presentation
- Ph 2 Data Monitoring Committee Recommends Continuing Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics